Involvement of COX-1 in A3 adenosine receptor-mediated contraction through endothelium in mice aorta

2007 ◽  
Vol 293 (6) ◽  
pp. H3448-H3455 ◽  
Author(s):  
Habib R. Ansari ◽  
Ahmed Nadeem ◽  
Stephen L. Tilley ◽  
S. Jamal Mustafa

We investigated whether A3 adenosine receptor (A3AR) is involved in endothelium-mediated contraction through cyclooxygenases (COXs) with the use of wild-type (WT) and A3 knockout (A3KO) mice aorta. A3AR-selective agonist, Cl-IBMECA, produced a concentration-dependent contraction (EC50: 2.9 ± 0.2 × 10−9 M) in WT mouse aorta with intact endothelium (+E) and negligible effects in A3KO +E aorta. At 10−7 M, contractions produced by Cl-IBMECA were 29% in WT +E, while being insignificant in A3KO +E aorta. Cl-IBMECA-induced responses were abolished in endothelium-denuded tissues (−E), in both WT and A3KO aorta. A3AR gene and protein expression were reduced by 74 and 72% ( P < 0.05), respectively, in WT −E compared with WT +E aorta, while being undetected in A3KO +E/−E aorta. Indomethacin (nonspecific COXs blocker, 10−5 M), SC-560 (specific COX-1 blocker, 10−8 M), SQ 29549 (thromboxane prostanoid receptor antagonist, 10−6 M), and furegrelate (thromboxane synthase inhibitor, 10−5 M) inhibited Cl-IBMECA-induced contraction significantly. Cl-IBMECA-induced thromboxane B2 production was also attenuated significantly by indomethacin, SC-560, and furegrelate in WT +E aorta, while having negligible effects in A3KO +E aorta. NS-398 (specific COX-2 blocker) produced negligible inhibition of Cl-IBMECA-induced contraction in both WT +E and A3KO +E aorta. Cl-IBMECA-induced increase in COX-1 and thromboxane prostanoid receptor expression were significantly inhibited by MRS1523, a specific A3AR antagonist in WT +E aorta. Expression of both A3AR and COX-1 was located mostly on endothelium of WT and A3KO +E aorta. These results demonstrate for the first time the involvement of COX-1 pathway in A3AR-mediated contraction via endothelium.

2011 ◽  
Vol 25 (S1) ◽  
Author(s):  
Mohammed S. El‐Awady ◽  
Habib R Ansari ◽  
Daniel Fil ◽  
Stephen L Tilley ◽  
S. Jamal Mustafa

2008 ◽  
Vol 36 (9) ◽  
pp. 2569-2575 ◽  
Author(s):  
Yoshiaki Inoue ◽  
Yu Chen ◽  
Reinhard Pauzenberger ◽  
Mark I. Hirsh ◽  
Wolfgang G. Junger

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 13164-13164
Author(s):  
S. Bar Yehuda ◽  
S. Stemmer ◽  
D. Castel ◽  
A. Ohaion ◽  
S. Cohn ◽  
...  

13164 Background: The A3 adenosine receptor (A3AR) belongs to the family of the Gi-protein associated receptors and is highly expressed in various solid tumor tissues. The high receptor expression is reflected also in the peripheral blood mononuclear cells (PBMNC) of the cancer patients. Synthetic agonists to A3AR such as IB-MECA and Cl-IB-MECA (CF101 and CF102, respectively) suppress the development of melanoma, colon and prostate carcinoma in vitro and in vivo. The molecular mechanism involves de-regulation of the Wnt and the NF-kB signal transduction pathways. In this study we looked at A3AR expression in tumor and PBMNC of hepatocellular carcinoma (HCC) patients. In addition, receptor status model and the effect of CF102 on tumor development were examined in an HCC rat. Methods: A3AR mRNA expression level was examined in paraffin embedded slides derived from human HCC samples. A3AR protein expression was evaluated in human PBMNC by Western blot (WB) analysis. Rat HCC was established by inoculating N1S1 cells to the liver. Oral treatment with CF102, administered BID, was initiated 24h after tumor inoculation. A3AR and key growth regulatory proteins expression level in tumor lesions and PBMNC was tested by WB analysis. Results: A3AR was found to be highly expressed in the human HCC tumor tissue and the PBMNC compared to normal adjacent and PBMNC from healthy subjects, respectively. Similar data were found in tumor and PBMNC derived from N1S1 hepatoma bearing rats. In tumor lesions from CF102 treated animals, down-regulation of PKB/Akt, IKK, NF-κB and TNF-α, members of the NF-kB pathway was noted. In addition de-regulation of the Wnt pathway was observed by up-regulation of GSK-3β and down-regulation of β-catenin, Lef/Tcf and c-Myc, resulting in tumor growth inhibition. Conclusion: CF102, a small orally bioavailable molecule, binds to the A3AR which is highly expressed on tumor cells and via the de-regulation of the NF-kB and Wnt pathway induces inhibition of HCC growth. No significant financial relationships to disclose.


1993 ◽  
Vol 70 (05) ◽  
pp. 822-825 ◽  
Author(s):  
B Hoet ◽  
J Arnout ◽  
H Deckmyn ◽  
J Vermylen

SummaryRidogrel, a combined thromboxane receptor antagonist and thromboxane synthase inhibitor (1), inhibits platelet aggregation. Following stimulation with arachidonic acid, cAMP-levels are increased in human platelets preincubated with ridogrel, this is due to the known reorientation of the metabolism of the formed endoperoxides towards adenylate cyclase stimulating prostaglandins.Pretreatment of resting platelets with UDCG-212, a cAMP-phosphodiesterase inhibitor (2), also inhibits platelet aggregation induced by arachidonic acid, concomitant with an increase in cAMP levels, due to an inhibition of its breakdown. Under basal conditions, cAMP also is increased.By combining the two drugs, a more than additive action was observed on platelet aggregation and on both resting and stimulated platelet cAMP content. The appropriate combination may result in a more effective antiplatelet strategy.


1985 ◽  
Vol 54 (03) ◽  
pp. 612-616 ◽  
Author(s):  
A J Carter ◽  
S Heptinstall

SummaryThe platelet aggregation that occurred in whole blood in response to several aggregating agents (collagen, arachidonic acid, adenosine diphosphate, adrenaline and thrombin) was measured using an Ultra-Flo 100 Whole Blood Platelet Counter. The amounts of thromboxane B2 produced were measured by radioimmunoassay. The effects of various inhibitors of thromboxane synthesis and the effects of apyrase, an enzyme that destroys adenosine diphosphate, were determined.Platelet aggregation was always accompanied by the production of thromboxane B2, and the amounts produced depended on the nature and concentration of the aggregating agent used. The various inhibitors of thromboxane synthesis - aspirin and flurbiprofen (cyclo-oxygenase inhibitors), BW755C (a cyclo-oxygenase and lipoxygenase inhibitor) and dazoxiben (a selective thromboxane synthase inhibitor) - did not markedly inhibit aggregation. Results obtained using apyrase showed that adenosine diphosphate contributed to the aggregation process, and that its role must be acknowledged when devising means of inhibiting platelet aggregation in vivo.


2013 ◽  
Vol 13 (9) ◽  
pp. 1048-1068 ◽  
Author(s):  
Changliang Deng ◽  
Feng Luan ◽  
Maykel Cruz- Monteagudo ◽  
Fernanda Borges ◽  
M. Natalia D. S. Cordeiro

Sign in / Sign up

Export Citation Format

Share Document